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36 A Novel Aptamer-Based Enzymatic Assay for the Diagnosis of Malaria 
Roderick Dirkzwager (HKU) 
(Supervisor: Dr. Julian A Tanner, HKU) 
 
Malaria causes nearly 1 million annual fatalities in lesser developed regions in South East Asia 
and Africa. Symptoms of malaria are unspecific (fever, vomitting, headache etc.) meaning 
without laboratory equipment reliable diagnosis is problematic. Point-of-care antibody-based 
dipsticks are available on the market but the cost and instability of antibodies in heat and 
humidity limits their widespread use. Aptamers are short oligonucleotide sequences which 
selectively bind their targets and present as stable and affordable alternatives to antibodies in 
point-of-care tests. Aptamers against the malaria antigen Plasmodium falciparum lactate 
dehydrogenase (pLDH) have been developed in our lab with nanomolar Kd affinities and are 
specific enough to not interact with human LDH isoforms. We have incorporated these 
aptamers into a novel 96-well plate based malaria test called the aptaMAL. Surface bound 
aptamers capture pLDH out of blood samples and after wash steps and reagent addition, the 
solution turns blue if the test is positive. The colour is achieved by coupling a colour changing 
reaction to the enzyme activity of pLDH. The test has been found to be effective on rat blood 
samples spiked with the pLDH antigen at very low concentrations (aptaMAL limit of detection 
10 ng/mL, typical pLDH concentration in infected blood 3000 ng/mL). This aptaMAL 
mechanism shows potential to be incorporated into a point-of-care device format which would 
be affordable, reliable and have no need for any complex equipment or unstable reagents. 
 
 
37 Nuclear translocation of HDAC4 in Alzheimer’s disease human brain 
Shen Xuting (HKUST) 
(Supervisor: Professor Karl Herrup, HKUST) 
 
Histone deacetylases (HDACs) play a crucial role in histone modification whose inappropriate 
function has been linked to Alzheimer’s disease (AD). HDAC4, as a member of the family of 
HDACs, presents predominantly in the cytoplasm of the neurons of the human brain. As our 
lab has shown previously, its nuclear translocation is mediated by a decreased level of ATM 
(ataxia telangiectasia [A-T], mutated), a multi-functional protein kinase whose deficiency leads 
to A-T. Based on the fact that both A-T and AD are neurodegenerative disease involving 
modification of the histone code, there arises the possibility that ATM may play a role in AD. 
Using the nuclear translocation of HDAC4 as a marker, previous work has proved the 
involvement of ATM deficiency in AD diagnosed with clinical dementia rating (CDR) system. 
Extending that work, we performed immunohistochemistry on the human brain samples 
grouped by Braak stages. This staging scheme is based largely on the extent and location of 
deposits of hyperphosphorylated tau. We found a significant decrease in ATM activity in 
hippocampus between groups of age-matched controls with normal cognition, mild cognitive 
impairment (MCI) and AD. Consistent with previous work, we found that the CA2 sub-region 
was the area with the highest levels of nuclear HDAC4. Extending this work, we show for the 
first time a substantial correlation of this phenotype with the presence of ectopic cell cycle 
markers. Taken together, the results confirm the importance of the decrease in ATM activity 
during the pathogenesis of AD. 
 
 
 
 
 
 
 
 
 
 
